Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

被引：27
作者：
Cortes, Jorge E.
Tallman, Martin S.
Schiller, Gary
Trone, Denise
Gammon, Guy
Goldberg, Stuart
Perl, Alexander E.
Marie, Jean Pierre
Martinelli, Giovanni
Levis, Mark
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.494.494
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
494
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant
    Cortes, Jorge E.
    Perl, Alexander E.
    Dombret, Herve
    Dohner, Hartmut
    Steffen, Bjoern
    Rousselot, Philippe H.
    Martinelli, Giovanni
    Estey, Elihu
    Shah, Neil P.
    Burnett, Alan K.
    Gammon, Guy
    Trone, Denise
    Levis, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial (vol 20, pg 986, 2019)
    Cortes, J. E.
    Khaled, S.
    Martinelli, G.
    LANCET ONCOLOGY, 2019, 20 (07) : E346 - E346
  • [23] Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
    Yu, Sijian
    Zhang, Yu
    Yu, Guopan
    Wang, Yu
    Shao, Ruoyang
    Du, Xin
    Xu, Na
    Lin, Dongjun
    Zhao, Weihua
    Zhang, Xiong
    Xiao, Jie
    Sun, Zhiqiang
    Deng, Lan
    Liang, Xinquan
    Zhang, Hongyu
    Guo, Ziwen
    Dai, Min
    Shi, Pengcheng
    Huang, Fen
    Fan, Zhiping
    Liu, Qiong
    Lin, Ren
    Jiang, Xuejie
    Xuan, Li
    Liu, Qifa
    Jin, Hua
    JOURNAL OF INTERNAL MEDICINE, 2024, 295 (02) : 216 - 228
  • [24] Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study
    Yu, Sijian
    Liu, Qifa
    Zhang, Yu
    Yu, Guopan
    Wang, Yu
    Shao, Ruoyang
    Liu, Qiong
    BLOOD, 2023, 142
  • [25] Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)
    Perl, Alexander E.
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Khaled, Samer K.
    Kraemer, Alwin
    Martinelli, Giovanni
    Russell, Nigel H.
    Chang, Ken C.
    Kato, Kazunobu
    Yan, Yuhu
    Xu, Li-An
    Korkhov, Sergey
    Gunnel, Tobias
    Sumi, Hiroyuki
    Lesegretain, Arnaud
    Berisha, Flora
    Mires, Derek
    Benzohra, Aziz
    Isoyama, Takeshi
    Dos Santos, Cedric
    Levis, Mark J.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
    Cortes, Jorge
    Perl, Alexander E.
    Dohner, Hartmut
    Kantarjian, Hagop
    Martinelli, Giovanni
    Kovacsovics, Tibor
    Rousselot, Philippe
    Steffen, Bjorn
    Dombret, Herve
    Estey, Elihu
    Strickland, Stephen
    Altman, Jessica K.
    Baldus, Claudia D.
    Burnett, Alan
    Kramer, Alwin
    Russell, Nigel
    Shah, Neil P.
    Smith, Catherine C.
    Wang, Eunice S.
    Ifrah, Norbert
    Gammon, Guy
    Trone, Denise
    Lazzaretto, Deborah
    Levis, Mark
    LANCET ONCOLOGY, 2018, 19 (07) : 889 - 903
  • [27] Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Perl, Alexander E.
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Khaled, Samer K.
    Kramer, Alwin
    Martinelli, Giovanni
    Russell, Nigel H.
    Chang, Ken C. N.
    Mires, Derek E.
    Kato, Kazunobu
    Zhang, Yufen
    Korkhov, Sergey
    Wang, Zhenyu
    Gunnel, Tobias
    Sumi, Hiroyuki
    Isoyama, Takeshi
    Lesegretain, Arnaud
    Berisha, Flora
    Dos Santos, Cedric E.
    Levis, Mark J.
    BLOOD, 2019, 134
  • [28] Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
    Wang, Jianxiang
    Jiang, Bin
    Li, Jian
    Liu, Ligen
    Du, Xin
    Jiang, Hao
    Hu, Jianda
    Yuan, Menghe
    Sakatani, Taishi
    Kadokura, Takeshi
    Takeuchi, Masato
    Izuka, Shunsuke
    Girshova, Larisa
    Tan, Jerome
    Bondarenko, Sergey N.
    Wong, Lily L. L.
    Khuhapinant, Archrob
    Martynova, Elena
    Hasabou, Nahla
    Tiu, Ramon V.
    BLOOD, 2021, 138
  • [29] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
    O'Brien, Maureen
    Alonzo, Todd
    Cooper, Todd
    Levine, John
    Brown, Patrick
    Slone, Tamra
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Quan, Jackie
    Simcock, Mathew
    Weiss, Daniel
    Zimmerman, Linda
    Kolb, Edward
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [30] A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
    Smith, Catherine C.
    Levis, Mark J.
    Frankfurt, Olga
    Pagel, John M.
    Roboz, Gail J.
    Stone, Richard M.
    Wang, Eunice S.
    Severson, Paul L.
    West, Brian L.
    Le, Mai H.
    Kayser, Sabine
    Lam, Bao
    Hsu, Henry H.
    Zhang, Chao
    Bollag, Gideon
    Perl, Alexander E.
    BLOOD ADVANCES, 2020, 4 (08) : 1711 - 1721
12345